Personalized Medicine: A new era of treating illnesses tailored to individual patients

Pharmacogenomics is a rapidly advancing field that studies how our genetic makeup affects our responses to Personalized Medicine. Variations in patients' DNA sequences determine differences in drug absorption, distribution, metabolism, and elimination.

Cancer is an area where precision medicine is having an especially dramatic impact. Comparing a patient's tumor DNA to large databases of known cancer-related gene mutations can match the tumor profile to targeted drugs called biomarkers or immunotherapies that attack vulnerabilities unique to that tumor.

For example, about 15 percent of breast cancers are HER2-positive, meaning they have too many copies of a growth-promoting gene called HER2. A drug that specifically targets HER2, trastuzumab, has transformed treatment for these patients.

Get More Insights: Personalized Medicine
(https://www.trendingwebwire.com/personalized-medicine-analysis/
)
Personalized Medicine: A new era of treating illnesses tailored to individual patients Pharmacogenomics is a rapidly advancing field that studies how our genetic makeup affects our responses to Personalized Medicine. Variations in patients' DNA sequences determine differences in drug absorption, distribution, metabolism, and elimination. Cancer is an area where precision medicine is having an especially dramatic impact. Comparing a patient's tumor DNA to large databases of known cancer-related gene mutations can match the tumor profile to targeted drugs called biomarkers or immunotherapies that attack vulnerabilities unique to that tumor. For example, about 15 percent of breast cancers are HER2-positive, meaning they have too many copies of a growth-promoting gene called HER2. A drug that specifically targets HER2, trastuzumab, has transformed treatment for these patients. Get More Insights: Personalized Medicine (https://www.trendingwebwire.com/personalized-medicine-analysis/ )
Personalized Medicine Size and Trends
The global transthyretin amyloid cardiomyopathy treatment market is estimated to be valued at US$ 1943.69 Bn in 2024
0 Kommentare 0 Anteile